Article Information
History
- May 9, 2022.
Article Versions
- Version 1 (January 6, 2022 - 10:13).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Amanda Zheutlin1,†,
- Miles Ott2,†,
- Ran Sun3,
- Natalia Zemlianskaia1,
- Meagan Rubel4,
- Jennifer Hayden1,
- Breno Neri1,
- Tripthi Kamath1,
- Najat Khan1,
- Sebastian Schneeweiss5 and
- Khaled Sarsour3,*
- 1Data Sciences, Research & Development, Janssen Pharmaceuticals; Titusville, NJ
- 2Data Sciences, Research & Development, Janssen Pharmaceuticals; Cambridge, MA
- 3Data Sciences, Research & Development, Janssen Pharmaceuticals; South San Francisco, CA
- 4Data Sciences, Research & Development, Janssen Pharmaceuticals; San Diego, CA
- 5Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School; Boston, MA
- ↵*Corresponding author contact information: Khaled Sarsour, 260 E Grand Ave, South San Francisco, CA 94080 ksarsour{at}its.jnj.com Telephone: 650-296-0719
↵† Authors contributed equally.
Posted May 09, 2022.
Durability of protection post-primary COVID-19 vaccination in the US: matched case-control study
